Alten, Rieke http://orcid.org/0000-0002-3395-4412
Feist, Eugen
Lorenz, Hanns-Martin
Nüßlein, Hubert
Voll, Reinhard E.
Chartier, Melanie
Elbez, Yedid
Rauch, Christiane
Funding for this research was provided by:
Bristol-Myers Squibb (N/A)
Article History
Received: 1 February 2019
Revised: 10 June 2019
Accepted: 17 June 2019
First Online: 12 July 2019
Compliance with ethical standards
: The study was conducted in accordance with the Declaration of Helsinki, [CitationRef removed] the International Conference for Harmonization Guideline for Good Clinical Practice, [CitationRef removed], and the Good Epidemiological Practice guideline, [CitationRef removed] with local institutional review board/independent ethics committee approval. All patients provided written informed consent in accordance with local laws.
: RA: research grants: Bristol-Myers Squibb. EF: honoraria and grant support: Bristol-Myers Squibb, Novartis, Pfizer, Roche, MSD, AbbVie, Lilly, and Sanofi. H-ML: consulting fees: AbbVie, Bristol-Myers Squibb, Roche-Chugai, UCB, MSD, GSK, Sobi, Medac, Novartis, Janssen-Cilag, AstraZeneca, Pfizer, and Actelion. HN: consulting fees: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB. REV: honoraria and/or grant support: AbbVie, Bristol-Myers Squibb, Celgene, MSD, Novartis, Pfizer, Roche, Sanofi, and Takeda. MC: employment: Bristol-Myers Squibb. YE: consultancy fees: Bristol-Myers Squibb. CR: employee and shareholder: Bristol-Myers Squibb. All authors have full control of all primary data and agree to journal review of data, if requested.